Medicine and Health Sciences Commons^™

Computational Pharmacology: Simulating Circuits Of The Brain For Drug Development, Patrick D. Roberts

Systems Science Friday Noon Seminar Series

The pharmaceutical industry is approaching unsustainable research costs to develop new drug therapies for mental disease because of the high failure rate in clinical trials. These failures are due to limitations of pre-clinical studies in animal models that fail to predict the efficacy of new drugs in human subjects. The gap between pre-clinical trials and clinical trials is particularly difficult in complex mental diseases such as schizophrenia because of the complex dynamics of the brain and the multiple chemical pathways that drugs can affect.

However, many biological mechanisms associated with schizophrenia are now understood, and computational power and methods have …

Evaluating The Target Pipeline In A Pharmaceutical Acquisition, Daniel Vass

Business and Economics Honors Papers

Many firms in the pharmaceutical industry turn to acquisitions when faced with gaps in their drug development pipelines and patent expirations as an alternative to making long-term investments in internal research and development. Investors are generally negative on this strategy, and upon the announcement of a pharmaceutical acquisition the stock of the acquiring firm often drops. This decline in share price creates an opportunity for the investor who can identify the characteristics of a target firm that increase the probability that the transaction will ultimately be a success, as measured by the subsequent appreciation in the acquirer's stock. It is …